Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 726 results for innovative

  1. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.

  2. SYNE-COV for predicting COVID-19 outcomes (MIB264)

    NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .

  3. TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)

    NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .

  4. SecurAcath for securing cerebrospinal fluid catheters (MIB107)

    NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .

  5. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MIB210)

    NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .

  6. Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

    Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.

  7. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  8. Reslizumab for treating severe eosinophilic asthma (TA479)

    Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.

  9. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

  10. NICE glossary

    The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.

  11. Risdiplam for treating spinal muscular atrophy (TA755)

    Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.

  12. Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

    Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.

  13. Bosutinib for previously treated chronic myeloid leukaemia (TA401)

    Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.

  14. Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)

    Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  15. Helge for detecting haemolysis (MIB225)

    NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .